We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Biogen Inc.
Health Care · Biotechnology
MS-cashflow run-off race against new-franchise ramp. Tecfidera/Tysabri/Vumerity declining mid-to-high single digits as oral MS competition (Vumerity cannibalization, $NVS Kesimpta, $ROG Ocrevus) compresses pricing. The structural re-rate hinges on Leqembi adoption curve (slow but accelerating post-CMS coverage + subcutaneous AHEAD-3-45 readout) plus Skyclarys ex-US launches and Zurzuvae uptake in PPD.
- Leqembi (with $ESAIY): only approved disease-modifying anti-amyloid AD therapy alongside $LLY donanemab; subQ auto-injector filing accelerates outpatient adoption
- Skyclarys (Friedreich's ataxia) - only approved DMT, ~$370k/yr orphan pricing, EU + Japan launches still ramping
- Spinraza royalty stream still meaningful even as $NVS Zolgensma / Roche Evrysdi compete in SMA
- Cost-cut program (~$1B+ run-rate) and balance sheet (~$2B net cash post-Reata) allow tuck-in M&A
- MS franchise declining ~10%/yr; revenue base shrinking faster than Leqembi ramps
- Leqembi uptake disappointing vs Street model - ARIA monitoring + infusion logistics + payer friction
- $7.3B Reata + $7.3B Sage deals look expensive vs current contribution (Zurzuvae sales weak)
- Aduhelm withdrawal (2024) burned credibility on Alzheimer's commercial execution
- IRA Medicare price negotiation eligible windows on legacy MS drugs
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for BIIB - only listicles and opinion pieces, which we filter out by default. See everything anyway.